Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 9,544 matching trials from the live ClinicalTrials.gov search.

Filters: Birmingham, Alabama Clear all

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 63
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more

Conditions: Ovarian Cancer, Primary Peritoneal Carcinoma
Interventions: Å6 subcutaneous injection; Drug
Lead sponsor: Ångstrom Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 24
States / cities: Birmingham, Alabama • Casa Grande, Arizona • Fresno, California + 21 more

Conditions: Metastatic Breast Cancer
Interventions: biomarker study; Other
Lead sponsor: Side-Out Foundation; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 4 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 174
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 146 more

Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab; Drug · Other · Radiation + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 634
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more

Conditions: Oral Leukoplakia
Interventions: Pioglitazone hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 11
States / cities: Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more

Conditions: Neuroblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, melphalan, topotecan hydrochloride, vincristine sulfate, autologous bone marrow transplantation, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Downey, California + 76 more

Conditions: Narcolepsy
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more

Conditions: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Interventions: secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more

Conditions: Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions: Glucagon for Injection (Fresenius Kabi USA); Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: ADHD With Sleep Onset Insomnia
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL)
Interventions: TRU-016 (anti-CD37 protein therapeutic); Drug
Lead sponsor: Aptevo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 7
States / cities: Birmingham, Alabama • Augusta, Georgia • Boston, Massachusetts + 4 more

Conditions: Obesity, Weight Loss
Interventions: Rimonabant (SR141716); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,045 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 42 more

Conditions: Sinusitis
Interventions: Zithromax (azithromycin) 500mg tablets, Endoscopic Sinus Surgery, Blood sampling for hematology, Blood sampling for plasma chemistry profile, Serum pregnancy test (for women of child-bearing potential); Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 11 more

Conditions: Refractive Error, Cataract
Interventions: spectacles, Cataract Surgery; Device · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 17
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 33
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more

Conditions: Her2 Negative Breast Cancer Patients
Interventions: MM-121, Placebo, Exemestane; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 18
States / cities: Birmingham, Alabama • Glendale, Arizona • Anaheim, California + 13 more

Conditions: Non-Alcoholic Fatty Liver Disease, Obesity
Interventions: Moderately carbohydrate-restricted diet, Fat-restricted diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 10 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: bosentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more

Conditions: Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Intracranial Hemorrhages
Interventions: Vitamin E, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 4 Hours
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 12 more

Conditions: Venous Thromboembolism
Interventions: Apixaban, Standard of Care; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 0 Days to 17 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 84
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more

Conditions: HIV Infections
Interventions: Therapeutic Drug Monitoring (TDM); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more

Conditions: Hemoglobin SC Disease
Interventions: Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more

Conditions: ACL Reconstruction
Interventions: Methyl Prednisolone (MP), Standard Post-Operative Pain Control, Surgeon's Standard ACL Postoperative Regimen; Drug · Combination Product
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Pioglitazone for Oral Premalignant Lesions

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Obese Patients With or Without Comorbidities (RIO-North America)

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

Improving Vision and Quality of Life in the Nursing Home

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

Vitamin E for Extremely Preterm Infants

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction